SWOT Analysis for Bliss GVS Pharma Ltd. - Opportunity

Add SWOT widget to your site/app

Benjamin Graham Value Screen

Companies with current TTM PE Ratio less than 3 Year, 5 Year and 10 Year PE

Strong Performer, Under Radar Stocks (DVM)

Companies with 10% increase in share price over three months, with rising net profit growth

Undervalued Growth Stocks

Stocks seeing month price declines, good financial durability, and newly affordable valuations (subscription)

Relative Outperformance versus Industry over 1 Year

Companies with high TTM EPS Growth

Best Bargains Screener: Above line growth, Below line valuations

PEG lower than Industry PEG

High Momentum Scores (Technical Scores greater than 50)

Efficient in managing Assets to generate Profits - ROA improving since last 2 year

Growth in Net Profit with increasing Profit Margin (QoQ)

Growth in Quarterly Net Profit with increasing Profit Margin (YoY)

Companies with Low Debt

Annual Net Profits improving for last 2 years

Book Value per share Improving for last 2 years

Companies with Zero Promoter Pledge

Negative to Positive growth in Sales and Profit with Strong Price momentum

Volume Shockers

Stocks Outperforming their Industry Price Change in the Quarter

Companies with growing costs YoY for long term projects

Decline in Quarterly Net Profit (YoY)

Increasing Trend in Non-Core Income

High volume, top losers

RSI indicating price weakness

Top Losers

Companies with improving valuation scores after share price falls

Promoters increasing shareholding QoQ

Rising Delivery Percentage Compared to Prev Day

Average Affordability - Stocks with Medium Trendlyne Valuation Score versus Benchmarks

Average Bullish Trend - Stocks with Medium Trendlyne Momentum Score versus Benchmarks